Femasys is trading at $2.45, down 5.04%, as rising Treasury yields, persistent inflation concerns and risk-off sentiment pressure growth-oriented healthcare stocks. - Biotech is broadly lower, with XBI down 2.04%; the 10-year Treasury yield reached approximately 5.14% on September 24. - No company-specific announcement was identified for September 24, 2026; recent coverage instead lists earlier developments, including Femasys’ September 15 expansion announcement.